News headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.810355663548 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- Joseph L. Goldstein Sells 2,000 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock (americanbankingnews.com)
- Why Intellia Therapeutics Is Plunging Today (finance.yahoo.com)
- IBB, AMGN, GILD, REGN: ETF Outflow Alert – Nasdaq (nasdaq.com)
- Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on … – PR Newswire (press release) (prnewswire.com)
- Bull of the Day: Regeneron (REGN) – Nasdaq (nasdaq.com)
A number of equities research analysts have commented on REGN shares. BidaskClub raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. BMO Capital Markets set a $444.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Argus cut their target price on shares of Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a research report on Thursday, December 28th. Finally, Cowen reaffirmed a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $449.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the company earned $3.04 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 28.9% on a year-over-year basis. equities research analysts expect that Regeneron Pharmaceuticals will post 19.2 EPS for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $340.00, for a total transaction of $680,000.00. Following the transaction, the director now owns 14,000 shares in the company, valued at approximately $4,760,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/2018/03/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-regeneron-pharmaceuticals-regn-share-price/2031068.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.